Phase 3 INSPIRE Study for EPP & XLP – Now Recruiting!

Participant recruitment is now underway for a phase 3 study of MT-7117, an investigational treatment for Erythropoietic Protoporphyria (EPP) and X-Linked Porphyria (XLP).

INSPIRE is a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.

Fast Facts:

  • 10 US sites open: 

    • Boston, MA (2); Colombus, OH; Detroit, MI; Kansas City, KS; Los Angeles, CA; Miami, FL; New York, NY; Seattle, WA; and Winston-Salem, NC.

    • Site in California opening soon- please fill out an interest form to be matched to a site that is convenient to you.

  • Age 12+ with confirmed EPP/XLP diagnosis

  • Have not previously received dersimelagon

  • 150 participants needed globally

  • The study drug is an oral medication

  • Study includes an optional open-label extension

Please click here to submit a confidential interest form.

Previous
Previous

Cimetidine Research Study in Patients with EPP and XLP

Next
Next

Longitudinal Study of the Porphyrias